1 Two multicentre, parallel group, randomised, double-blind, double-dummy comparison studies were conducted between
isoxicam in the usual dose of 200 mg once daily and
naproxen 500 mg twice daily. 2 The drugs were administered for 4 weeks to 230 patients suffering from
osteoarthritis of the hip and/or knee in the first trial and to 249 patients suffering from
rheumatoid arthritis in the second. 3 The studies compared treatments for both safety and overall effectiveness in the relief of
pain. 4 In the
osteoarthritis trial, overall
pain was reduced by both drugs after 2 weeks of
therapy but only
isoxicam produced further improvement after 4 weeks. 5
Isoxicam produced reductions comparable to those produced by
naproxen in
pain on standing from the sitting position,
pain on walking, and
pain on movement of the affected joint, after 2 and 4 weeks. 6 After 4 weeks,
isoxicam given once daily in the morning was significantly more effective than
naproxen given in the morning and the evening in relieving not only total
pain as assessed by a visual analogue scale but, as importantly, night
pain. 7 Compared to
naproxen therapy,
isoxicam therapy was associated with significantly more patients whose disease state was improved at 2 weeks, as assessed by physicians. 8 In the
rheumatoid arthritis trial,
isoxicam was equally as effective as
naproxen in reducing joint tenderness, joint swelling, and
pain; at 4 weeks there was a trend in favour of
isoxicam in reduction of joint swelling and
pain. 9
Isoxicam reduced morning stiffness significantly more than
naproxen after 4 weeks; this trend was apparent at 2 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)